Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer. Fujimoto N, Tsubonuma Y, Nagata Y, Minato A, et al. Anticancer Res 2023;43:3841-3847.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fujimoto N, Tsubonuma Y, Nagata Y, Minato A, et al. Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer. Anticancer Res 2023;43:3841-3847.
PMID: 37648316